Hanking-KY Plans to List on Innovation Board by End of May, Initiates Global Licensing Negotiations for New Anti-Cancer Drug
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
Hanking-KY, a company specializing in immuno-oncology drug development, plans to list on the Innovation Board by the end of May. Its new anti-cancer drug, HCB101, secured an early licensing deal worth US02 million last year and is now in global licensing negotiations.